Opioid-use Disorder Clinical Trial
Official title:
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of a Novel Subcutaneous Depot Formulation of Buprenorphine (INDV-6200) in Healthy Volunteers
INDV-6200 is being developed for the treatment of opioid dependency and is expected to provide sustained buprenorphine plasma concentrations. The study will be done in healthy volunteers and will administer a non-therapeutic dose of INDV-6200. Study Period 1 will evaluate the oral tolerability of sublingual (SL) buprenorphine dosed over 3 days. Period 2 will administer the investigational medicinal product (IMP) or volume matched placebo.
INDV-6200 is a novel buprenorphine subcutaneous (SC) depot formulation being developed for
the treatment of opioid dependency. It is expected to provide sustained buprenorphine plasma
concentrations to achieve consistent and optimal occupancy of mu-opioid receptors in the
brain, for the treatment of opioid use disorder. A related subcutaneously injected,
extended-release product of buprenorphine base has demonstrated sustained therapeutic plasma
levels of buprenorphine over a minimum of 1 month.
Extensive experience gained from RBP-6000 allowed the development of an allometric model
which has been used to predict the in vivo performance of INDV-6200. The preclinical
pharmacokinetic (PK) data and the predictions from allometric scaling indicate that INDV-6200
is expected to display a similar PK profile as RBP-6000. Therefore, the main objective of
this study is to investigate the PK properties of this new, related formulation using a low
dose with a large safety margin.
Period 1 will be used to evaluate the oral tolerability of SL buprenorphine (SUBUTEX;
non-investigational medicinal product [nIMP]) dosed over 3 days. Period 2 will involve
administration of the IMP (INDV-6200) or volume-matched placebo; (low dose in Cohort A or
alternative dose in optional Cohort B), to evaluate PK and safety of this novel formulation.
Both periods will also include a series of Nalorex (nIMP) administrations to antagonise
potential opioid effects from buprenorphine.
Based on modeling and simulation, the dose proposed for Cohort A is expected to give similar
plasma buprenorphine exposure to that obtained with the same SC dose of RBP-6000. If
buprenorphine plasma exposure is lower than predicted, there is an optional second cohort
(Cohort B), which may be used to explore another dose level of INDV-6200 predicted.
As this is a Phase I study, using a non-therapeutic dose of INDV-6200, the most relevant
population is healthy subjects as this allows a characterisation of safety, tolerability and
PK for a new molecular entity in a homogeneous population without potential biases from a
patient population. In order to avoid any interaction with other medication, no co-medication
will be allowed.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04157062 -
An Open-Label Trial of Repetitive Transcranial Magnetic Stimulation for Opioid Use Disorder
|
N/A | |
Enrolling by invitation |
NCT04527926 -
STEPuP: Prenatal Provider Education and Training to Improve Medication-assisted Treatment Use During Pregnancy
|
N/A | |
Completed |
NCT04505540 -
Start Treatment and Recovery for Opioid Use Disorder
|
N/A | |
Completed |
NCT03065049 -
Transforming Recovery Through Exercise and Community
|
N/A | |
Completed |
NCT04080037 -
Assessing Opioid Care Practices Using CPV Patient Simulation Modules
|
N/A | |
Recruiting |
NCT05118204 -
Randomized Trial of Buprenorphine Microdose Inductions During Hospitalization
|
Phase 4 | |
Suspended |
NCT05001789 -
Cognitive Functioning in Opioid Use Disorder
|
N/A | |
Active, not recruiting |
NCT04650386 -
Examining an Adaptive Approach to Providing Psychosocial Support to Buprenorphine Patients
|
N/A | |
Enrolling by invitation |
NCT04991974 -
Opioid Use Disorder Treatment Linkage at Sexual Health Clinics Using Buprenorphine
|
Phase 2/Phase 3 | |
Completed |
NCT04122755 -
Single Ascending Dose Study of ALA-1000
|
Phase 1 | |
Recruiting |
NCT05028998 -
COVID-19-Related Opioid Treatment Policy Evaluation
|
||
Recruiting |
NCT04927143 -
Encouraging Abstinence Behavior in a Drug Epidemic
|
Phase 2 | |
Recruiting |
NCT05049460 -
Adjunctive Transcranial Stimulation to Reduce Impulsivity in Opiate Use Disorder
|
N/A | |
Completed |
NCT05047627 -
Digital Intervention to Treat Anxiety and Depression Among Persons Receiving Treatment for Opioid Use Disorder
|
N/A | |
Active, not recruiting |
NCT04129580 -
reSET-O RCT (Randomized Controlled Trial)
|
N/A | |
Recruiting |
NCT03923374 -
Opioid Use Disorder in Pregnancy in Long-Term Maternal/Infant Outcomes
|
||
Completed |
NCT04464421 -
SMART Effectiveness Trial
|
N/A | |
Completed |
NCT04056182 -
Lofexidine for Management of Opioid Withdrawal With XR-NTX Treatment
|
Phase 2 | |
Suspended |
NCT02687360 -
Imaging the Effects of rTMS on Chronic Pain
|
N/A | |
Completed |
NCT03766893 -
Medication Maintenance Therapy in Community Pharmacy Settings
|
Early Phase 1 |